Nobuyuki Torii
Overview
Explore the profile of Nobuyuki Torii including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torii N, Ichihara A, Mizuguchi Y, Seki Y, Hashimoto E, Tokushige K
Intern Med
. 2018 Jun;
57(12):1741-1745.
PMID: 29910217
The patient was a 23-year-old man who was diagnosed with severe hypoxemia and liver dysfunction after suffering from sudden difficulty breathing. At 2 years of age, he had been diagnosed...
2.
Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, et al.
Intern Med
. 2017 Sep;
56(22):2993-3001.
PMID: 28943585
Objective Hyponatremia is frequently observed in patients with decompensated liver cirrhosis and it is also related to a poor prognosis. The vasopressin V2-receptor antagonist tolvaptan is used to treat cirrhotic...
3.
Kogiso T, Hashimoto E, Ito T, Hara T, Ikarashi Y, Kodama K, et al.
Intern Med
. 2016 Oct;
55(20):2957-2963.
PMID: 27746432
A 56-year-old man was diagnosed with aplastic anemia and paroxysmal nocturnal hemoglobinuria at 43 years of age and treatment with cyclosporin A was started. Liver cirrhosis, ascites, and thrombus in...
4.
Kogiso T, Yamamoto K, Kobayashi M, Ikarashi Y, Kodama K, Taniai M, et al.
Hepatol Res
. 2016 Sep;
47(9):835-844.
PMID: 27670393
Aim: The vasopressin V2 receptor antagonist tolvaptan has been used for the treatment of cirrhotic patients with ascites; however, no predictor of efficacy and prognosis has been developed. We evaluated...
5.
Ikarashi Y, Kogiso T, Hashimoto E, Yamamoto K, Kodama K, Taniai M, et al.
Hepatol Res
. 2016 Mar;
47(3):E201-E209.
PMID: 27027269
Poorly controlled diabetes mellitus (DM) patients sometimes show serum transaminase elevations due to steatohepatitis. However, we experienced four cases with type 1 DM with sharp elevations in serum transaminases that...
6.
Kogiso T, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, Torii N, et al.
Clin J Gastroenterol
. 2015 Sep;
8(5):323-9.
PMID: 26342292
Re-infection by the hepatitis C virus (HCV) occurs rapidly after liver transplantation (LT), and spontaneous clearance of HCV is rare under immunosuppressive conditions. Here, we report on two patients who...
7.
Kogiso T, Tokushige K, Hashimoto E, Ikarashi Y, Kodama K, Taniai M, et al.
Hepatol Res
. 2015 Jul;
46(3):E194-200.
PMID: 26123753
Aim: Recently, the short-term efficacy of the vasopressin V2 receptor antagonist tolvaptan for the treatment of ascites in cirrhosis was reported. However, the long-term effects remain unknown. Here, we report...
8.
Kogiso T, Tokushige K, Hashimoto E, Miyakata C, Taniai M, Torii N, et al.
Hepatol Res
. 2015 Jan;
45(12):1251-5.
PMID: 25594663
Primary hyperoxaluria (PH) is a rare, autosomal recessive disorder characterized by overproduction of oxalate caused by a deficiency in a hepatic enzyme. The excess oxalate combines with calcium in the...
9.
Matsushita N, Hashimoto E, Tokushige K, Kodama K, Tobari M, Kogiso T, et al.
Intern Med
. 2014 Jun;
53(12):1249-57.
PMID: 24930642
Objective: Ornithine carbamoyltransferase (OCT) is a liver-specific mitochondrial matrix enzyme and potential biomarker of liver fibrosis. This study investigated the OCT levels in patients with chronic liver disease with or...
10.
Tokushige K, Hashimoto E, Kodama K, Tobari M, Matsushita N, Kogiso T, et al.
J Gastroenterol
. 2013 Mar;
48(12):1392-400.
PMID: 23478936
Background: Biomarker for usefulness in diagnosing advanced fibrosis in nonalcoholic fatty liver disease (NAFLD) is expected. In order to discover novel biomarkers for NAFLD and its pathogenesis, we performed matabolomics...